High association of peroxiredoxins with lung cancer

Our plain-English summary of High association of peroxiredoxins with lung cancer, by Y. Soini, V.L. Kinnula (Lung Cancer, 2012).

The study

• Authors: Y. Soini, V.L. Kinnula
• Journal: Lung Cancer
• Published: 2012;78(2):167
• Type of article: Letter, Comment
• Cited by: 6 articles, as counted by NIH iCite
• Read it: PubMed · Publisher

Summary of the article

In this letter to the editor, the authors commented on an article by Rostila et al. that examined peroxiredoxins (PRX) 1 and 2 and tropomyosin 4 as potential biomarker proteins in the serum of patients with lung cancer and of individuals exposed to asbestos fibers and/or tobacco smoke. They summarized Rostila et al.'s data postulating that PRX1 is upregulated in lung cancer while PRX2 is likely downregulated, and the report that serum PRX1 and PRX2 levels were inversely associated with smoking, and PRX1 with lung cancer. The letter writers stated that these results were in line with their own earlier work on mesotheliomas, in which all six mammalian PRXs were studied and found to be over-expressed. They noted that Rostila et al. had not cited their earlier studies of PRXs in human lung and in various lung cancers. In that lung cancer study, PRXs 1, 2, 4 and 6 were elevated, expression varied considerably between tumor subtypes, and some PRXs (mainly 2 and 6) were associated with cancer grade or progression. The authors described the regulation of PRX1 by NRF2. They cited their recent findings that NRF2 expression was associated with poor prognosis in lung cancer, and that sulfiredoxin predicted poor outcome in patients receiving cytotoxic drugs or radiation therapy and was associated with smoking history. They agreed that PRXs 1 and 2 and tropomyosin 4 are worthy of further research in lung cancer and other pulmonary diseases.

PubMed has no abstract for this study, and the article doesn't print one. We wrote this summary from the full article with the help of AI. It is not the authors' wording.

In plain English

This item is a letter to the editor and reports no new data. The authors commented on an article by Rostila and colleagues that studied peroxiredoxins (PRX) 1 and 2 and tropomyosin 4 as possible serum biomarkers in patients with lung cancer and people exposed to asbestos fibers and/or tobacco smoke. As the letter describes it, that article proposed that PRX1 is increased in lung cancer while PRX2 is likely decreased. The letter writers said these results fit their own earlier studies. One found all six PRXs over-expressed in mesotheliomas. Another found PRXs 1, 2, 4 and 6 elevated in lung cancer. They also cited their recent article finding that expression of NRF2, a protein that regulates PRX1, was associated with poor prognosis in lung cancer patients. The authors noted that Rostila and colleagues had not cited two of their earlier works: the first study of PRXs in human lung and the study of all six PRXs in lung cancers. The authors concluded that they agreed PRXs 1 and 2 and tropomyosin 4 deserve further research in lung cancer and other lung diseases.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Letter to the editor commenting on a published article (Rostila et al.). It contains no new study data.
• Who was studied: The letter studied no population of its own. It discusses the Rostila et al. study of serum from patients with lung cancer and from individuals exposed to asbestos fibers and/or tobacco smoke.
• Exposure: Asbestos fibers (type not specified) and/or tobacco smoke, as studied in the Rostila et al. article. The letter itself measured no exposure.
• Main results:
  • As described in the letter, Rostila et al. proposed that PRX1 is upregulated in lung cancer while PRX2 is likely downregulated. This is that article's finding, not this letter's.
  • In the letter writers' earlier mesothelioma work (cited, not new), all six PRXs were studied and found to be over-expressed in mesotheliomas.
  • In the letter writers' earlier lung cancer study (cited, not new), PRXs 4 and 6, as well as PRXs 1 and 2, were elevated in lung cancer.
  • In the letter writers' recent article (cited, not new), NRF2 expression was associated with poor prognosis of patients with lung cancer.
  • The letter writers stated that Rostila et al. failed to cite two of their earlier works: the first study on PRXs in human lung and the first one on all six PRXs in various human lung cancers and disease stages.
• The authors' conclusion: The authors stated that they agreed with Rostila et al. that PRXs 1 and 2 and tropomyosin 4 are worthy of further research in lung cancer and other pulmonary diseases.

Topics

The National Library of Medicine indexes this study under subjects our site covers: Lung cancer.

Medical terms in this study, explained in our Lexicon: Lung Cancer, Biomarker, Mesothelioma, Prognosis.

Related studies

• Peroxiredoxins and tropomyosins as plasma biomarkers for lung cancer and asbestos exposure — A. Rostila, A. Puustinen, et al. (2012)
• High level of Ets-related gene expression has high specificity for prostate cancer: a tissue microarray study of 11 483 cancers — S. Minner, A.M. Luebke, et al. (2012)
• CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells — B. Davidson (2016)
• Soluble mesothelin-related peptides (SMRP) - high stability of a potential tumor marker for mesothelioma — D.G. Weber, D. Taeger, et al. (2007)
• High tumor cell platelet-derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma — H. Ollila, J. Paajanen, et al. (2021)
• Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor α in high-grade serous ovarian carcinoma — E.T. Taube, C. Denkert, et al. (2017)

Browse more research in Lung Cancer, or return to medical research.